Dan Werb


Scientist, Li Ka Shing Knowledge Institute

Email: dwerb@ucsd.edu
Tel: 858-205-8262
Twitter: @dmwerb


Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Global Public Health at the University of California, San Diego, where he is Principal Investigator of PRIMER: Preventing Injecting by Modifying Existing Responses, a five-year multi-site cohort study tasked with developing interventions to preventing entry into injection drug use. This study is funded through the inaugural United States National Institute on Drug Abuse Avenir Award, a USD$1.5 million research grant for creative new investigators proposing highly innovative research at the intersection of HIV and substance use. At the LKSKI, Dr. Werb is Director and Scientific Board Chair of the International Centre for Science in Drug Policy (ICSDP; www.icsdp.org), a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations. At the ICSDP, Dr. Werb is a sought after source of expertise on drug policy, and has appeared in media related to his work in every global hemisphere. He has helped oversee communications campaigns around such high profile projects as the Vienna Declaration (www.viennadeclaration.com). He has also published extensively on global drug policy and HIV policy. Dr. Werb is a former Trudeau Foundation Scholar and a Canadian Institutes of Health Research postdoctoral fellow. He conducts extensive knowledge translation on drug policy and public health, through print and radio journalism, and is the winner of a 2014 Canadian National Magazine Award for his popular science writing.

Please note: Dr. Werb is not taking any summer students in 2018.

Recent Publications

  1. Meyers, SA, Scheim, A, Jain, S, Sun, X, Milloy, MJ, DeBeck, K et al.. Gender differences in the provision of injection initiation assistance: a comparison of three North American settings. Harm Reduct J. 2018;15 (1):59. doi: 10.1186/s12954-018-0270-6. PubMed PMID:30514384 PubMed Central PMC6280353.
  2. Goodman-Meza, D, Medina-Mora, ME, Magis-Rodríguez, C, Landovitz, RJ, Shoptaw, S, Werb, D et al.. Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border. Am J Public Health. 2018; :e1-e10. doi: 10.2105/AJPH.2018.304767. PubMed PMID:30495992 .
  3. Rafful, C, Jain, S, Sun, X, Strathdee, SA, Garfein, RS, Cuevas-Mota, J et al.. Identification of a Syndemic of Blood-Borne Disease Transmission and Injection Drug Use Initiation at the US-Mexico Border. J. Acquir. Immune Defic. Syndr. 2018;79 (5):559-565. doi: 10.1097/QAI.0000000000001858. PubMed PMID:30222661 PubMed Central PMC6231973.
  4. Beletsky, L, Baker, P, Arredondo, J, Emuka, A, Goodman-Meza, D, Medina-Mora, ME et al.. The global health and equity imperative for safe consumption facilities. Lancet. 2018;392 (10147):553-554. doi: 10.1016/S0140-6736(18)31469-7. PubMed PMID:30152386 .
  5. Scheim, A, Werb, D. Integrating supervised consumption into a continuum of care for people who use drugs. CMAJ. 2018;190 (31):E921-E922. doi: 10.1503/cmaj.180824. PubMed PMID:30087127 PubMed Central PMC6078768.
  6. Ospina-Escobar, A, Magis-Rodríguez, C, Juárez, F, Werb, D, Bautista Arredondo, S, Carreón, R et al.. Comparing risk environments for HIV among people who inject drugs from three cities in Northern Mexico. Harm Reduct J. 2018;15 (1):27. doi: 10.1186/s12954-018-0225-y. PubMed PMID:29776368 PubMed Central PMC5960140.
  7. Guise, A, Melo, J, Mittal, ML, Rafful, C, Cuevas-Mota, J, Davidson, P et al.. A fragmented code: The moral and structural context for providing assistance with injection drug use initiation in San Diego, USA. Int. J. Drug Policy. 2018;55 :51-60. doi: 10.1016/j.drugpo.2018.02.009. PubMed PMID:29524733 PubMed Central PMC5970953.
  8. Melo, JS, Mittal, ML, Horyniak, D, Strathdee, SA, Werb, D. Injection Drug Use Trajectories among Migrant Populations: A Narrative Review. Subst Use Misuse. 2018;53 (9):1558-1570. doi: 10.1080/10826084.2017.1416404. PubMed PMID:29364762 PubMed Central PMC6033671.
  9. Rafful, C, Orozco, R, Rangel, G, Davidson, P, Werb, D, Beletsky, L et al.. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs. Addiction. 2018;113 (6):1056-1063. doi: 10.1111/add.14159. PubMed PMID:29333664 PubMed Central PMC5938130.
  10. Melo, JS, Garfein, RS, Hayashi, K, Milloy, MJ, DeBeck, K, Sun, S et al.. Do law enforcement interactions reduce the initiation of injection drug use? An investigation in three North American settings. Drug Alcohol Depend. 2018;182 :67-73. doi: 10.1016/j.drugalcdep.2017.10.009. PubMed PMID:29169035 PubMed Central PMC6219752.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy